Delivery Order SPE2DB24D2205-SPE2DB25FEFKS
Award Date 7/25/25
Potential Completion Date 7/28/25
Potential Value $43K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,291.75 for Dupixent 300 mg/2 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, asthma,...
- The Defense Logistics Agency awarded a delivery order valued at $11,651.25 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitive award, which carries no set-aside designation, is issued under firm fixed pricing and represents a child order to AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will...
- The Defense Logistics Agency awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectables on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and is being fulfilled from AmerisourceBergen's place of business in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on July 22, 2025, for Dupixent 300 mg/2 mL pens with a ceiling value of $14,474.85 under a firm fixed price arrangement. The award, which is not set-aside and competitively awarded, is scheduled for completion by July 23, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $74,194.57 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and specifies performance at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various allergic and...
- The Defense Logistics Agency awarded a $21,060.94 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 mL pens. This non-competitive, firm fixed price delivery order is expected to be completed by July 28, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $217,423.50 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025. This firm fixed-price delivery order, which carries an ultimate completion date of July 29, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Pennsylvania...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 mL pens totaling $20,114.60 with completion scheduled for July 22, 2025. This competitive, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency awarded a $26,836.77 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 24, 2025, with completion targeted for July 25, 2025. This firm fixed-price contract represents a single delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was not set-aside and resulted from competitive procurement,...